Simponi (golimumab) is a new option for treating ulcerative colitis in adults

December 2013

Simponi (golimumab) is a new option for treating ulcerative colitis in adults.

It's already indicated for use in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Simponi is the second tumour necrosis factor (TNF) blocker approved for ulcerative colitis after Remicade (infliximab).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Med Adherence strategies to improve med adherence
Vaccines vaccine selection and administration
Gastroenterology Simponi (golimumab) is a new option for treating ulcerative colitis in adults
Obesity & Weight Loss More obese patients will get bariatric surgery and need help with their meds afterward
HIV & AIDS New simplified guidelines for HIV prophylaxis after a needlestick
Pneumonia more emphasis on prevention and treatment of community-acquired pneumonia
Acute Pain more focus on the management of acute low back pain to counter the increasing use of opioids and benzodiazepines
Fungal Infections Emtrix, a new nail fungus treatment
Antipsychotics More pharmacists are questioning the use of antipsychotics in patients WITHOUT psychotic disorders
Fentanyl Patches Improper disposal of fentanyl patches (Duragesic, etc) is causing accidental exposures and opioid toxicity
Oral Health Patients are asking for help choosing tooth whiteners